Testing HF50 safety in advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial tests a new drug called HF50 in people with advanced cancers that have spread or cannot be surgically removed. The goal is to see if HF50 is safe and whether it helps shrink tumors in patients whose cancer has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent and follow study instructions
- You have advanced cancer (solid tumor) that is unresectable, metastatic, or has failed standard treatment
- You are in good overall health with expected survival of at least 6 months and minimal daily activity limitations (ECOG score 0–1)
- You have at least one measurable tumor on imaging and adequate blood, liver, and kidney function based on recent blood tests
- You have not received chemotherapy, radiation, or immunotherapy within the past 2 weeks (4 weeks for certain drugs) and have recovered from prior treatment side effects
- You do not have active autoimmune disease, uncontrolled high blood pressure, active infection, HIV, hepatitis, or symptomatic brain tumors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-4508 for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe, how the body processes it, and if it helps shrink tumors.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
This trial tests a new drug, HF50, in people with advanced solid tumors that are HER-2 positive or have low HER-2 levels. It may be an option if standard treatments have stopped working or are not tolerated.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.